NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $2.32 -0.07 (-2.93%) (As of 02:38 PM ET) Add Compare Share Share Today's Range$2.30▼$2.4050-Day Range$1.80▼$2.5052-Week Range$1.12▼$6.63Volume330,568 shsAverage Volume687,877 shsMarket Capitalization$532.08 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ProKidney alerts: Email Address ProKidney MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside92.3% Upside$4.50 Price TargetShort InterestBearish13.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 8 Articles This WeekInsider TradingSelling Shares$2,065 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.44) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 starsMedical Sector584th out of 927 stocksBiological Products, Except Diagnostic Industry97th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProKidney has only been the subject of 2 research reports in the past 90 days.Read more about ProKidney's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.81% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently decreased by 3.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 3.2 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for ProKidney this week, compared to 2 articles on an average week.Search Interest1 people have searched for PROK on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,065.00 in company stock.Percentage Held by Insiders41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to grow in the coming year, from ($0.44) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ProKidney's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About ProKidney Stock (NASDAQ:PROK)ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesSeptember 15 at 4:25 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Down to $2.38September 12, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) Coverage Initiated at GuggenheimSeptember 16, 2024 | Capital Trends (Ad)More Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.September 11, 2024 | markets.businessinsider.comBuy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease TreatmentSeptember 6, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) PT Lowered to $3.00September 5, 2024 | markets.businessinsider.comMaintaining Hold on ProKidney Amid Strategic Shifts and Regulatory UncertaintiesSeptember 5, 2024 | markets.businessinsider.comProKidney’s Hold Rating Maintained Amid Financing and Clinical UncertaintiesSeptember 5, 2024 | finance.yahoo.comProKidney drops Phase III CKD study to focus on US market and save up to $175mSeptember 16, 2024 | Capital Trends (Ad)More Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.September 4, 2024 | markets.businessinsider.comProKidney Reports Strategic Updates To Phase 3 Study Of Rilparencel; To Discontinue PROACT 2 StudySeptember 3, 2024 | msn.comProKidney revises Phase 3 program for lead assetSeptember 3, 2024 | globenewswire.comProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.August 27, 2024 | globenewswire.comProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 23, 2024 | seekingalpha.comThe Prognosis For ProKidney: UnclearAugust 16, 2024 | bizjournals.comProKidney resumes manufacturing and Phase 3 clinicals, extends cash runwayAugust 9, 2024 | globenewswire.comProKidney Reports Business Updates and Second Quarter 2024 Financial ResultsJuly 30, 2024 | finance.yahoo.comProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutionsJuly 25, 2024 | finance.yahoo.comChronic Kidney Disease for Seven Major Markets: US, France, Germany, Italy, Spain, UK, Japan Drug Forecasts and Analysis 2023-2033See More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/16/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+87.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,470,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-8.80% Debt Debt-to-Equity RatioN/A Current Ratio21.87 Quick Ratio21.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.84) per share Price / Book-0.50Miscellaneous Outstanding Shares229,344,000Free Float134,189,000Market Cap$550.43 million OptionableOptionable Beta1.10 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Bruce Culleton M.D. (Age 56)CEO & Director Comp: $657.93kDr. Timothy A. Bertram D.V.M. (Age 69)Ph.D., Founder Comp: $1.46MMr. James Coulston CPA (Age 47)Chief Financial Officer Comp: $533.15kMr. Todd C. Girolamo Esq. (Age 59)J.D., M.B.A., Chief Legal Officer & Secretary Comp: $541.59kMs. Mary Weger (Age 65)Chief People Officer Dr. Joseph M. Stavas M.D.M.P.H., Senior VP of Interventional Procedures & Patient SafetyDr. Darin J. Weber Ph.D. (Age 56)Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access Mr. Nikhil L. Pereira-KamathChief Business OfficerMr. Richard WilliamsSenior Vice President of Information TechnologyDr. Aparna Sahoo M.D.VP & Head of Global Clinical DevelopmentMore ExecutivesKey CompetitorsSocial Capital Suvretta Holdings Corp. IINASDAQ:DNABSocial Capital Suvretta Holdings Corp. IVNASDAQ:DNADVPC Impact Acquisition Holdings IINASDAQ:VPCBSOAR Technology AcquisitionNYSE:FLYASemper Paratus AcquisitionNASDAQ:LGSTView All CompetitorsInsiders & InstitutionsSusquehanna Fundamental Investments LLCBought 42,990 shares on 8/15/2024Ownership: 0.019%The Manufacturers Life Insurance Company Bought 24,566 shares on 8/15/2024Ownership: 0.011%AQR Capital Management LLCBought 20,518 shares on 8/15/2024Ownership: 0.009%Marshall Wace LLPBought 50,242 shares on 8/14/2024Ownership: 0.022%Federated Hermes Inc.Sold 89,983 shares on 8/8/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $1.78 at the beginning of the year. Since then, PROK stock has increased by 31.5% and is now trading at $2.34. View the best growth stocks for 2024 here. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) posted its earnings results on Friday, August, 9th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Who are ProKidney's major shareholders? Top institutional investors of ProKidney include Bank of New York Mellon Corp (0.08%), Rhumbline Advisers (0.03%), Marshall Wace LLP (0.02%) and Susquehanna Fundamental Investments LLC (0.02%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROK) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
